Innovation is part idea generation and part development. We build a model of "innovating-by-doing," whereby ideas come … to practitioners. Successful innovation requires that practitioners' ideas be developed through costly effort. Our model ….S. Medicare program on medical equipment innovation. Our model’s structure allows us to infer the Medicare program's aggregate …

I study the channels through which health insurance influences medical innovation. Following Medicare and Medicaid … per resident. Consistent with historical case studies, Medical innovation's determinants extend beyond the potential … revenues associated with global market size; a physician driven process of innovation-while-doing appears to play a central …

I study the channels through which health insurance influences medical innovation. Following Medicare and Medicaid … per resident. Consistent with historical case studies, Medical innovation's determinants extend beyond the potential … revenues associated with global market size; a physician driven process of innovation-while-doing appears to play a central …

Innovation is part idea generation and part development. We build a model of “innovating-bydoing,” whereby ideas come … to practitioners. Successful innovation requires that practitioners’ideas be developed through costly effort. Our model … program onmedical equipment innovation. Our model’s structure allows us to infer the Medicare program’saggregate effects. We …

.S. drug pricing system: Current law also provides weak incentives for medical innovation across wide areas, including vaccines … innovation not only slow the growth of U.S. life expectancy but also exacerbate racial disparities in health outcomes.High drug … prices and slow pharmaceutical progress are two facets of the same problem: a system that fails to reward medical innovation …

innovation. We use machine learning tools to develop new data describing the aspects of medical and mechanical innovations that … are emphasized in patent documents. Our analysis of historical patents yields three primary facts. First, we find that the …

proposals have been framed as issues of access and spending. If innovation incentives come up at all, it has primarily been … because pharmaceutical companies claim that reducing drug prices will threaten innovation by lowering the returns from their … patents.In fact, however, pharmaceutical access and innovation incentives are intimately related. Health insurance can change …